Prometheus Receives New York State Approval for PROMETHEUS® Crohn's Prognostic, the First Serogenetic Test to Predict Risk of Complications From Crohn's Disease
SAN DIEGO, Feb. 22, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today that it has received New York State approval for its proprietary PROMETHEUS® Crohn's Prognostic test. This novel and unique diagnostic represents a significant advance in the Prometheus Inflammatory Bowel Disease (IBD) franchise of diagnostic and prognostic tests, and complements the market-leading PROMETHEUS® IBD Serology 7.
The PROMETHEUS® Crohn's Prognostic test combines six serologic markers and three genetic mutation markers to provide physicians with a personalized serogenetic profile for their patients. This helps enable physicians to quantify these patients' risk of developing disease complications over time and is designed to provide information to assist physicians in determining optimal treatment strategies for their Crohn's patients.
"The proprietary PROMETHEUS® Crohn's Prognostic helps physicians in developing a more individualized treatment plan for each patient and better explain the risks and benefits of these treatments to their patients and their families," said Joseph M. Limber, President and CEO of Prometheus. "Prometheus is committed to continue its mission of contributing to personalized medicine by offering the GI community innovative tools to assist in the diagnosis, prognosis, and treatment of IBD patients."
A manuscript describing the Prometheus Crohn's Prognostic has recently been accepted for publication in the journal, Inflammatory Bowel Disease.
About Crohn's Disease
Crohn's disease is a chronic disorder that causes inflammation of the digestive or gastrointestinal tract. Symptoms of the disease include diarrhea, abdominal pain, fever and rectal bleeding. Crohn's patients may require long-term medical care, including multiple hospitalizations, surgeries and therapeutics. The condition can be difficult to manage clinically and consumes a substantial amount of healthcare resources in terms of physician time, procedures and medications. Crohn's disease is estimated to affect between 400,000 and 600,000 individuals in North America.
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.
SOURCE Prometheus Laboratories Inc.